Search
Search for Bupa recognised healthcare professionals and services.
+ any details

Dr Helen O'Donnell

Clinical oncology

 

  • Not Fee assured
Overview
COVID-19

This healthcare professional let us know that they are currently:

  • Accepting new patients
  • Available for:
    • Face-to-face consultations
    • Phone consultations

Last updated: 15 Apr 2020

Specialises in

  • Gynaecology
  • Urology

About us

Trained at Merton College, Oxford University and St George’s Hospital Medical School London and graduated in 1998.
Completed her post-graduate general medical training at The Bart’s and The London in 2002 and was accredited in Clinical Oncology in 2007 in London.
Prior to taking up Consultant post spent 2 years as a Clinical Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research.
Appointed as a Clinical Oncologist at The Royal Berkshire Hospital in September 2009.

Interested in the treatment of gynaecological cancers, prostate, bladder and renal cancers.
Specialises in Prostate Brachytherapy.
Currently Clinical Director and Lead Cancer Physician at the Berkshire Cancer Centre

Areas of interest

Brachytherapy; Prostate disease including prostate cancer; Urological oncology; Gynaecological oncology

Medical secretaries

Our qualifications & training
Our private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0004

    Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)

    Spire Dunedin Hospital (5-50)

  • X6581

    Clinical supervision of the delivery of a single fraction of radiotherapy - (1-5)

  • X0008

    Clinical supervision of external beam radiotherapy, for 16 or up to and including 30 fractions - (1-5)

    Spire Dunedin Hospital (1-5)

  • X6774

    Preparation for intermediate radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (1-5)

    Spire Dunedin Hospital (1-5)

  • BT211

    Planning for insertion and removal of a radioactive agent (brachytherapy) into prostate tumour - (1-5)

Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.